Sectors & Industries HealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Industry: Biotechnology

Value Growth Financials Momentum Sentiment Forecast Dividends Due Diligence

Biotech is Zen Rated F and is the 135th ranked industry out of 145 stock market industries

Ticker	Company	Price	1d %	1w %	1m %	3m %	6m %	1y %	3y %	5y %	10y %	52-week High	52-week Low	% off 52-week High	% off 52-week Low	Beta	Volume	Vol 1d %
IVA	INVENTIVA SA	$6.05	0.67%	7.08%	31.81%	91.15%	110.43%	237.99%	58.79%	-45.45%	N/A	$6.50	$1.60	6.92%	278.13%	0.32	27,300	-52.11%
DWTX	DOGWOOD THERAPEUTICS INC	$5.52	8.02%	10.18%	10.62%	15.72%	-7.38%	22.67%	-43.03%	N/A	N/A	$29.28	$1.62	81.15%	240.74%	0.83	67,600	164.06%
AIM	AIM IMMUNOTECH INC	$2.68	-6.94%	0.00%	3.88%	-72.00%	1,961.54%	892.59%	331.56%	21.82%	-97.02%	$20.35	$0.06	86.83%	4,153.97%	109.90	132,000	-91.04%
CMMB	CHEMOMAB THERAPEUTICS LTD	$2.64	5.60%	-0.38%	-22.35%	-44.72%	-43.10%	-57.96%	-71.67%	-96.05%	N/A	$9.84	$2.40	73.17%	10.00%	1.10	283,000	221.59%
CNTX	CONTEXT THERAPEUTICS INC	$0.91	0.78%	-5.99%	5.81%	39.78%	15.04%	-50.81%	-24.17%	N/A	N/A	$2.59	$0.49	64.86%	85.71%	0.97	102,000	-50.49%
ESLA	ESTRELLA IMMUNOPHARMA INC	$1.20	4.35%	8.11%	23.71%	27.66%	22.45%	23.71%	-88.07%	N/A	N/A	$1.78	$0.63	32.58%	90.48%	0.23	111,000	1,341.56%
INTS	INTENSITY THERAPEUTICS INC	$0.24	-2.02%	-2.02%	-19.54%	-20.59%	-88.09%	-93.31%	N/A	N/A	N/A	$4.00	$0.19	93.93%	31.35%	0.26	1,065,000	15.38%
INDP	INDAPTUS THERAPEUTICS INC	$3.49	6.40%	25.54%	-46.47%	-72.85%	-80.30%	-88.24%	-94.63%	-99.37%	-99.97%	$58.24	$2.22	94.01%	57.21%	1.12	14,697,000	3,819.20%
GTBP	GT BIOPHARMA INC	$0.77	0.92%	-1.79%	-32.63%	-79.79%	-68.26%	-63.25%	-98.58%	-99.25%	N/A	$4.10	$0.63	81.27%	21.90%	1.04	1,968,000	987.29%
ENTO	ENTERO THERAPEUTICS INC	$4.75	0.85%	-7.95%	150.00%	263.98%	173.46%	354.98%	-99.16%	-99.99%	N/A	$5.47	$0.96	13.16%	394.79%	0.54	92,000	109.09%
ICCC	IMMUCELL CORP	$6.03	-0.25%	1.17%	-3.52%	-11.19%	26.15%	67.04%	-23.18%	6.73%	-2.11%	$7.60	$3.38	20.66%	78.40%	0.24	7,200	453.85%
GNPX	GENPREX INC	$0.18	-3.24%	-23.18%	5.29%	-23.50%	-52.89%	-48.71%	-99.68%	-99.87%	N/A	$3.97	$0.14	95.49%	27.86%	1.19	3,264,000	-14.58%
IGC	IGC PHARMA INC	$0.40	2.30%	-2.44%	2.56%	29.03%	29.03%	14.29%	-8.88%	-62.62%	122.22%	$0.50	$0.25	19.68%	58.10%	0.85	294,000	-44.53%
IPHA	INNATE PHARMA SA	$1.78	-2.20%	-4.81%	-15.24%	-6.81%	-1.66%	-17.21%	-16.43%	-53.83%	N/A	$3.51	$1.29	49.30%	37.98%	0.58	6,700	-75.37%
ADAG	ADAGENE INC	$1.96	-2.97%	-4.39%	-17.30%	3.16%	16.67%	-12.50%	48.48%	N/A	N/A	$3.16	$1.33	37.97%	47.92%	0.31	10,700	-83.41%
CARM	CARISMA THERAPEUTICS INC	$0.29	7.81%	16.00%	21.85%	-28.57%	-24.68%	-70.65%	-96.27%	-98.92%	-99.41%	$1.27	$0.14	77.17%	104.23%	1.30	704,000	6.51%
ENTX	ENTERA BIO LTD	$1.82	1.68%	1.11%	-8.08%	-9.00%	0.28%	-5.36%	54.24%	43.31%	N/A	$2.79	$1.50	34.77%	21.25%	0.61	67,400	172.87%
ERNA	ERNEXA THERAPEUTICS INC	$1.14	1.79%	-14.29%	-23.49%	-40.00%	-66.91%	-94.02%	-98.27%	-99.89%	-99.99%	$18.75	$1.09	93.92%	4.59%	1.20	27,600	-76.41%
ADIL	ADIAL PHARMACEUTICALS INC	$0.34	2.69%	-1.71%	-10.42%	-26.81%	-50.93%	-65.60%	-96.44%	-99.02%	N/A	$1.30	$0.22	73.54%	56.36%	0.69	604,000	-31.44%
BBOT	BRIDGEBIO ONCOLOGY THERAPEUTICS INC	$11.70	-1.02%	2.45%	22.07%	9.86%	8.84%	11.96%	N/A	N/A	N/A	$12.50	$8.50	6.40%	37.65%	0.02	122,000	-55.64%
ETNB	89BIO INC	$14.70	0.00%	-1.14%	57.05%	47.74%	83.29%	99.73%	181.07%	-40.46%	N/A	$15.06	$4.16	2.39%	253.37%	1.03	6,156,000	6.27%
BRTX	BIORESTORATIVE THERAPIES INC	$1.43	-1.38%	-1.38%	-6.17%	-14.37%	-18.75%	-15.88%	-43.92%	-97.93%	-99.99%	$2.55	$1.21	43.92%	18.18%	0.64	171,000	252.58%
IBO	IMPACT BIOMEDICAL INC	$0.66	1.54%	-2.95%	14.63%	-28.48%	-70.09%	-72.47%	N/A	N/A	N/A	$6.17	$0.36	89.34%	81.77%	-0.92	144,000	29.73%
KTTA	PASITHEA THERAPEUTICS CORP	$0.73	2.39%	-0.82%	3.27%	-0.95%	-47.32%	-87.57%	-96.84%	N/A	N/A	$6.07	$0.65	88.02%	11.85%	0.26	70,000	117.39%
EXOZ	EXOZYMES INC	$15.48	6.27%	6.98%	66.27%	59.18%	22.76%	N/A	N/A	N/A	N/A	$23.99	$8.50	35.47%	82.12%	0.42	10,000	900.00%
CNSP	CNS PHARMACEUTICALS INC	$8.90	2.89%	11.53%	45.42%	-11.39%	-47.40%	-89.39%	-99.99%	-100.00%	N/A	$221.94	$4.93	95.99%	80.53%	0.73	10,800	-18.80%
DRTS	ALPHA TAU MEDICAL LTD	$4.11	-1.20%	0.49%	23.80%	36.32%	56.87%	79.87%	-25.00%	N/A	N/A	$4.39	$2.11	6.31%	94.79%	0.37	29,800	-69.28%
GNTA	GENENTA SCIENCE SPA	$3.16	1.12%	10.49%	-10.18%	3.78%	-23.49%	-22.45%	-37.67%	N/A	N/A	$7.28	$2.56	56.59%	23.44%	0.32	6,300	-19.23%
EVGN	EVOGENE LTD	$1.14	2.70%	-3.63%	-12.98%	-10.94%	-13.64%	-55.12%	-85.00%	-97.13%	-98.60%	$3.32	$0.95	65.66%	20.00%	0.97	32,400	-54.04%
GNFT	GENFIT SA	$3.55	0.45%	-18.01%	-13.41%	-7.55%	2.01%	-36.72%	-6.33%	-35.45%	N/A	$6.42	$2.55	44.73%	39.22%	0.21	7,400	-40.32%
GDTC	CYTOMED THERAPEUTICS LTD	$1.99	1.02%	6.70%	1.02%	-13.48%	-15.68%	34.46%	N/A	N/A	N/A	$4.05	$1.55	50.86%	28.39%	0.68	25,000	941.67%
XTLB	XTL BIOPHARMACEUTICALS LTD	$1.17	-1.68%	-3.31%	-1.68%	-0.85%	6.36%	-53.75%	-14.47%	-36.76%	-85.38%	$2.50	$0.86	53.22%	36.05%	0.64	3,400	-49.25%
IMMP	IMMUTEP LTD	$1.72	2.38%	6.83%	1.78%	5.52%	-6.01%	-24.23%	5.52%	4.24%	-59.05%	$2.71	$1.32	36.53%	30.30%	0.99	98,000	-32.88%
IMRN	IMMURON LTD	$1.94	0.26%	1.84%	10.57%	2.93%	7.50%	-29.38%	-13.38%	-72.67%	N/A	$2.87	$1.50	32.51%	29.00%	0.77	30,600	-19.47%

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Sep 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

1. Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH) is the #1 top biotech stock out of 634 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Theravance Biopharma (NASDAQ:TBPH) is: Value: B, Growth: A, Momentum: C, Sentiment: B, Safety: D, Financials: A, and AI: B.

Theravance Biopharma (NASDAQ:TBPH) has a Due Diligence Score of 39, which is 16 points higher than the biotech industry average of 23.

TBPH passed 12 out of 33 due diligence checks and has average fundamentals. Theravance Biopharma has seen its stock return 74.57% over the past year, overperforming other biotech stocks by 109 percentage points.

Theravance Biopharma has an average 1 year price target of $25.67, an upside of 82.42% from Theravance Biopharma's current stock price of $14.07.

Theravance Biopharma stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Theravance Biopharma, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ:RIGL) is the #2 top biotech stock out of 634 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Rigel Pharmaceuticals (NASDAQ:RIGL) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Rigel Pharmaceuticals (NASDAQ:RIGL) has a Due Diligence Score of 40, which is 17 points higher than the biotech industry average of 23.

RIGL passed 13 out of 33 due diligence checks and has average fundamentals. Rigel Pharmaceuticals has seen its stock return 78.94% over the past year, overperforming other biotech stocks by 113 percentage points.

Rigel Pharmaceuticals has an average 1 year price target of $32.00, an upside of 11.77% from Rigel Pharmaceuticals's current stock price of $28.63.

Rigel Pharmaceuticals stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Rigel Pharmaceuticals, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Biocryst Pharmaceuticals (NASDAQ:BCRX)

Biocryst Pharmaceuticals (NASDAQ:BCRX) is the #3 top biotech stock out of 634 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Biocryst Pharmaceuticals (NASDAQ:BCRX) is: Value: B, Growth: A, Momentum: D, Sentiment: A, Safety: C, Financials: B, and AI: A.

Biocryst Pharmaceuticals (NASDAQ:BCRX) has a Due Diligence Score of 15, which is -8 points lower than the biotech industry average of 23. Although this number is below the industry average, our proven quant model rates BCRX as a "A".

BCRX passed 5 out of 33 due diligence checks and has weak fundamentals. Biocryst Pharmaceuticals has seen its stock return 0.66% over the past year, overperforming other biotech stocks by 35 percentage points.

Biocryst Pharmaceuticals has an average 1 year price target of $17.13, an upside of 124.44% from Biocryst Pharmaceuticals's current stock price of $7.63.

Biocryst Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Biocryst Pharmaceuticals, 37.5% have issued a Strong Buy rating, 50% have issued a Buy, 12.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 6 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Dominari Holdings (NASDAQ:DOMH)

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 7.89%, which is 6 percentage points higher than the biotech industry average of 1.99%.

Dominari Holdings's dividend payout ratio of -13.4% indicates that its high dividend yield might not be sustainable for the long-term.

2. Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 2.48%, which is the same as the biotech industry average of 1.99%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 37.2% indicates that its dividend yield is sustainable for the long-term.

3. Novo Nordisk (Ozempic) (NYSE:NVO)

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 1.98%, which is the same as the biotech industry average of 1.99%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 41.4% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 1.79% in the last day, and up 1.91% over the last week. Fractyl Health was the among the top gainers in the biotechnology industry, gaining 32.67% yesterday.

Fractyl Health shares are trading higher. The company announced the pricing of a $60 million underwritten offering of 60 million shares at $1.00 each.

What are the most undervalued biotech stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

1. Harmony Biosciences Holdings (NASDAQ:HRMY)

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -30.86% in the past year. It has overperformed other stocks in the biotech industry by 3 percentage points.

2. Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has gained 89.06% in the past year. It has overperformed other stocks in the biotech industry by 123 percentage points.

3. Rigel Pharmaceuticals (NASDAQ:RIGL)

Rigel Pharmaceuticals (NASDAQ:RIGL) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Rigel Pharmaceuticals has a valuation score of 29, which is 15 points higher than the biotech industry average of 14. It passed 2 out of 7 valuation due diligence checks.

Rigel Pharmaceuticals's stock has gained 78.94% in the past year. It has overperformed other stocks in the biotech industry by 113 percentage points.

Are biotech stocks a good buy now?

58% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 74.88% over the next year.

2.75% of biotech stocks have a Zen Rating of A (Strong Buy), 4.44% of biotech stocks are rated B (Buy), 43.34% are rated C (Hold), 32.98% are rated D (Sell), and 16.49% are rated F (Strong Sell).

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is -103.63x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

Sectors & Industries HealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Biotech Stocks FAQ

1. Theravance Biopharma (NASDAQ:TBPH)

2. Rigel Pharmaceuticals (NASDAQ:RIGL)

3. Biocryst Pharmaceuticals (NASDAQ:BCRX)

1. Dominari Holdings (NASDAQ:DOMH)

2. Royalty Pharma (NASDAQ:RPRX)

3. Novo Nordisk (Ozempic) (NYSE:NVO)

1. Harmony Biosciences Holdings (NASDAQ:HRMY)

2. Puma Biotechnology (NASDAQ:PBYI)

3. Rigel Pharmaceuticals (NASDAQ:RIGL)

Company

Stock Tools

Stock Ideas

Sectors & IndustriesHealthcareBiotechnologyBest Biotech Stocks to Buy Now (2025)Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Biotech Stocks FAQ

1. Theravance Biopharma (NASDAQ:TBPH)

2. Rigel Pharmaceuticals (NASDAQ:RIGL)

3. Biocryst Pharmaceuticals (NASDAQ:BCRX)

1. Dominari Holdings (NASDAQ:DOMH)

2. Royalty Pharma (NASDAQ:RPRX)

3. Novo Nordisk (Ozempic) (NYSE:NVO)

1. Harmony Biosciences Holdings (NASDAQ:HRMY)

2. Puma Biotechnology (NASDAQ:PBYI)

3. Rigel Pharmaceuticals (NASDAQ:RIGL)

Company

Stock Tools

Stock Ideas

Sectors & Industries HealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.